


NASDAQ Co. Working Towards Advanced Treatments for Parkinson's Disease and Cancer. Inhibikase Therapeutics (NASDAQ: IKT)

NASDAQ Company Diligently Working Towards Advanced Treatments for Parkinson's Disease and Cancer: Inhibikase Therapeutics, Inc. (Stock Symbol: IKT)

ATLANTA, GEORGIA, UNITED STATES, June 7, 2021 /EINPresswire.com/ --NASDAQ Company Diligently Working



IKT is Currently Performing Phase I Clinical Trials

"

The acceleration of our Phase 1 study for IkT-148009 should allow us to move into evaluation of the safety, tolerability & pharmacokinetics in Parkinson's patients early in the third quarter of 2021." *Milton Werner, Ph.D., President and Chief Executive Officer of IKT* $\label{eq:stable} \square \texttt{N} \texttt{ASDAQ} \ \texttt{Listed} \ \texttt{Clinical-Stage} \ \texttt{Pharmaceutical} \ \texttt{Company}.$

Development of Effective Therapeutics for Parkinson's and Related Neurodegeneration Disorders as well as Certain Cancers.

□\$20.4 Million in Grant Funding Plus \$19 Million in Investor Capitol.

DBhase I Trials for Proprietary Therapy Drug on Accelerated Plan.

DExperienced Management, Consultants, Board of Directors and Nearly All KOLs in the Field on Scientific Advisory Board.

Experienced Management, Consultants, Board of Directors and Nearly All KOLs in the Field on Scientific Advisory Board.



Inhibikase Therapeutics, Inc. (NASDAQ: **IKT**) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. The IKT multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain.


IKT is currently performing its Phase I, randomized single ascending dose and multiple ascending dose study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. IKT is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. IKT is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

IKT is Driving Functional Reversal of Parkinson's Disease

□Multi-therapeutic pipeline with emphasis on neurodegeneration inside and outside of the brain.

Dur lead inhibitor of the Abelson





\$IKT Highlights

Management Team with Deep Experience in Drug **Development and Commercialization**

Executive Witton Werner, PhD President & CEO Previously, Dr. Werner served as Director of Research at Celtaxsys. From September 1996 until June 2007, Dr. Werner was a Head of the Laboratory of Molecular Biophysics at The Rockefeller University in New York City. Throughout his scientific career, Dr. Werner has been an innovator integrating chemistry, physics, and biology into a comprehensive approach to solving problems in medicine. Dr. Werner is the author or co-author of more than 70 research articles, reviews, and book chapters and has given lectures on his research work throughout the world.

Joseph Frattaroli , CPA Chief Financial Officer Mr. Frattaroli is a certified public accountant with more than 15 years of experience in public company filings and compliance for Nasdaq and OTC Markets companies. Previously, he provided chief financial officer and consulting services for several emerging biopharmaceutical and medical device companies, with responsibilities that included capital formation, deal structuring, and assisting private companies in their transition to becoming publicly traded SEC registrants.

Tegisarias. C: Warren Olanow, MD, Interim Chief Medical Officer and Chief Executive Officer of CLINTREX. Dr. Olanow is the former Henry P. and Georgette Goldschmidt Professor and Chairman of the Department of Neurology at the Mount Sinai School of Medicine Prior to joining Mount Sinai, he served on the faculties of McGill University. Duke University and the University of South Florida. He is the former President of the Movement Disorder Society, Dak President of the International Society of Moutor Disturbances, and former Treasurer of the American Neurological Association. He has served on the scientific Advisory Board of the Bachmann-Strauss Parkinson Foundation and of the Dystomia Foundation. Dr. Olanow is the former Co-Editor-in-Chief of the journal Movement Disorders. Dr. Olanow Neurosci Chief Ch



Xenetic

NIH

Icahn School of Medicine

CLINTRES

\$IKT Management

Tyrosine Kinase (c-Abl), IkT-148009, halts and reverses functional loss in animal models that recreate progressive human disease.

DEive clinical programs in neurodegeneration and one clinical program in oncology by close of 2021.

Dongoing Phase 1 trial with IkT-148009 reaches therapeutic drug exposures seen in animal models at just 25 mg oral dose 1x/day in humans.

IMultiple patent families for lead compound with expiration of 2036 and beyond **1**\$20.4 million in grants and contracts from NIH, DoD, the Michael J. Fox Foundation, and the Georgia Research Alliance, all peer-reviewed

1\$19 million in investor capital since 2018.

□ Bighly experienced and respected management team, consultants, Board of Directors, and nearly all KOLs in the field on Scientific Advisory Board

First Quarter 2021 Highlights of Recent Activity

On May 17thIKT reported financial results for the first quarter ended March 31, 2021, and highlighted recent developments.

Board of Directors

Hennis Berman Tals been a co-founder, toa'd member, tends Twester In many private biotechnology and the sed investor In many private biotechnology and advisory and venue capital firm and was co-founder solutions and the set of Melino Venues, LLC a advisory and venue capital firm and was co-founder Secutive Vice President of Corporate Development of advisory and venue capital firm and was co-founder to the president of Corporate Development of advisory and venue capital firm and the set of the secutive venue of the first software-sa-service anise, which was acquired by Awams (Intera, Inc. (and build preside considering prometer), which was acquired by build, set of the set of the security of the security and the security of the security of the security of the ting retrovius, which was acquired an onand (a water treatment company), which was acquired by and (a water treatment company), which was acquired by and (a water treatment company). Which was acquired by the (a water treatment company), which was acquired by and (a water treatment company). Which was acquired by and (a water treatment company), which was acquired by and (a water treatment company). Which was acquired by and (a water treatment company), which was acquired by and (a water treatment company). Which was acquired by and (b water treatment company). Which was acquired by and (b water treatment company). Which was acquired by and (b water treatment company). Which was acquired by and (b water treatment company). Which was acquired by and (b water treatment company). Which was acquired by and (b water treatment company). Which was acquired by and (b water treatment company). Which was acquired by and (b water treatment company). Which was acquired by and (b water treatment company). Which was acquired by and (b water treatment company). Which was acquired by and (b water treatment company). Which was acquired by and (b water treatment company). Which was acquired by

r. Paul Grint, MD has more than two decades of experience biologics and small-releacy tesparch and development, cluding the successful approval and commercialization of release the successful approval and commercialization of arease also, on the Board of Amplys Pharmasouticals, on the Board of Board of Amplys Pharmasouticals, on the drate allo, on the Board of Amplys Pharmasouticals, on the order a board of Board of Amplys Pharmasouticals, on the drate allo, on the Board of Amplys Pharmasouticals, and the Directors of AmpliPh Biocciences. Dr. Grint has also aborationes, Kalypays, Pitzer, IDEC Pharmaculticals, and aborationes, Kalypays, Pitzer, IDEC Pharmaculticals, and aborationes, Kalypays, Pitzer, IDEC Pharmaculticals, and aborationes of Paylines, and a subsidier of the Report Science of Payline, Directorial the Report 1. Marys Hospital College, University of London and a Collega.

\$IKT Board of Directors

Industry-Leading Advisors

Professor of Neurology, University of South Floridi College of Medicine - Director USF Parkinson's Disease and Movement Disorders Cente Jeffrey Kordower, PhD

Alla V and Solomon Jesmer Professor of Aging Neurological Sciences Rush University Medical Cente Dr. Ken Mare

Neurodegenerative Disorde Dr. Ted Dawson, MD, PF Neurodegeneration and Stem Cell Programs, Institute Cell Engineering, Departments of Neurology, Institute Pharmacology, and Molecular Sciences - The Joh

Dr. Valina Dawson, P Neurodegeneration and Stem Cell Programs, Institute Cell Engineering, Departments of Neurology Physiol The Johns Hopkins University School of Medic Dr. Warcza Dlanow, MD. EPC

Henry P. and Georgette Goldschmidt Professor a Chairman Emeritus, Mount Sinai School of Medici Clintrex, Ir Dr. Karl Kieburtz, MD, MP Pohent I. Jourt Perofesera in Neuroleous, Senior Associa-

Dean for Clinical Research, Director of the Clinic & Translational Science Institute, Founder Center (f Human Experimental Therapeutics (CHET)- University Rochester Medical Center Clintrex, In Dr. Jay Pasricha, MBBS, MI Director, Johns Hopkins Center for Neurogastroenterolog

□Accelerated timelines for Phase 1 Study of IkT-148009 for the treatment of PD and associated GI Disorders: In February 2021 IKT commenced patient dosing in its Phase

1 study evaluating the safety, tolerability and pharmacokinetics of IkT-148009, the Company's novel brain penetrant Abelson tyrosine kinase (c-Abl) inhibitor with the potential to modify Parkinson's disease and its gastrointestinal complications. In April 2021, IKT announced that it had accelerated the timeline for completion of the study based on early data that provided the opportunity to seek regulatory approval to commence dosing of PD patients in the third quarter of 2021, much earlier than previously anticipated.

Advancing chronic toxicology studies of IkT-148009 to permit long-term dosing in patients: In January 2021 IKT initiated 3- and 6-month long-term toxicology studies of IkT-148009 in mice and 3- and 9-month long-term toxicology studies of IkT-148009 in primates as required to obtain regulatory approval for chronic administration of IkT-148009 in patients. IKT has completed 3month toxicology studies and is presently completing its histopathology analysis in preparation for submission of the data for regulatory review early in the third quarter of 2021. IKT expects to complete 6- and 9-month toxicology studies in the fourth quarter of 2021.

Initiated clinical batch manufacturing and pill formulation of IkT-001Pro. In February, 2021, IKT initiated clinical batch manufacturing and final product formulation of IkT-001Pro, the IKT prodrug formulation of Imatinib, designed as a potentially safer, better tolerated treatment for Imatinib-sensitive cancers such as stable-phase Chronic Myeloid Leukemia (CML). IKT expects to file an Investigational New Drug (IND) application in the third quarter of 2021, with initiation of clinical development as soon as practicable after the filing, subject to FDA acceptance of the IND.

The acceleration of the Phase 1 study for its lead candidate, IkT-148009 should allow IKT to move into evaluation of the safety, tolerability and pharmacokinetics in Parkinson's patients early in the third quarter of 2021. Concurrently, IKT is advancing two long term toxicology studies in

animals, which will allow for chronic administration of IKT-148009 in patients following FDA review and acceptance.

In the third quarter of 2021, IKT plans to file its IND application for IKT-001Pro, which holds the potential to be a safer and better tolerated treatment for cancers such as CML and expects to initiate clinical development as soon as practicable following the submission of the IND application.

For more information on Inhibikase (ITK) visit: www.inhibikase.com

DISCLAIMER: FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. FPS/CA is NOT affiliated in any manner with any company mentioned herein. FPS/CA is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FPS/CA's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. FPS/CA has been compensated \$500 by a third party for dissemination of this article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

SOURCE: CorporateAds.com

IKT Inhibikase Therapeutics, Inc. +1 678-392-3419 email us here Visit us on social media: Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/542853315

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2021 IPD Group, Inc. All Right Reserved.